levaes is currently available in limited geographies. Please contact us if you would like more information.
Contact Us

About Us

Renovia was formed to better diagnose, treat, and potentially improve the lives of millions of women through a platform of innovative sensor technologies combined with a digital health platform. This allows precise, cost-effective visualization and treatment of weakened pelvic floor muscles in real time, while collecting actionable compliance and progress data on women’s pelvic health. Restoring pelvic health by strengthening pelvic floor muscles through clinically benefiting solutions is paramount to treating the underlying causes of Pelvic Floor Disorders.

We are combining the development of innovative FDA cleared Medical Devices with state-of-the-art patient based App technology and data management systems to empower patients to take back control of their pelvic floor muscles. Our Medical Devices and Mobile App (software designed to run on Smartphones and other mobile devices) utilizes patented technology, micro-sensors, and Bluetooth communications designed to provide enhanced value-based care, track progress and reinforce compliance/adherence.

Renovia’s Leadership team offers extensive talent and experience in disciplines critical to understanding the designing & development, engineering, regulatory, medical, compliance, project management, finance and commercialization of medical products and therapeutics that are transformational to our patients, caregivers and Healthcare Professionals.

Our Values

  • Be passionate and determined for patients and customers
  • Execute with highest standards of ethics and integrity
  • Unwavering accountability
  • Inspire a sense of urgency
  • Focus on imaginative innovation and delivering results
  • Pursue life and work with purpose, humility and fun

Discovering and developing innovative solutions and technology to help individuals suffering from specific pelvic floor disorders.

Leadership Team

Marc Beer
Co-Founder, Chairman & CEO

Marc brings more than 25 years of development and commercialization experience in biotechnology, pharmaceuticals, devices, and diagnostics. Marc founded Renovia with Ray Inglesias, MD and Yolanda Lorié in 2016 and successfully closed a Series A financing with leading healthcare venture capital funds.

Marc is the former Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Marc took the company public in October 2010. The Company’s first marketed product, JUXTAPID® (lomitapide) was approved by the US Food and Drug Administration in December 2012 for homozygous familial hypercholesterolemia. During his tenure, JUXTAPID obtained marketing approval in 36 countries. Additionally, Aegerion acquired its second product, MYALEPT® (metreleptin), approved in the US for generalized lipodystrophy, an ultra-rare disease.

In April 2000, Marc became the Founding CEO of ViaCell, a biotechnology company specializing in the collection, preservation, and development of umbilical cord blood stem cells, and over a period of seven years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc’s leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (NYSE: PKI).

While serving as CEO of ViaCell, Marc also served as a member of the board of directors of Erytech Pharma, a publicly traded biopharmaceutical company. Prior to ViaCell, Marc held various positions within Genzyme, most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing rare disease populations on a global scale.

Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (NYSE: ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts and served on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board.

Marc is also Founding Chairman of the board of directors and chairman of the compensation committee of Good Start Genetics, Inc. and he is the Founding Chairman of the board, chairman of the compensation committee and member of the audit committee of Minerva Neurosciences Inc. (NASDAQ: NERV); and a member of the Miami University Business Advisory Council and previously a member of the Notre Dame Research and Commercialization Advisory Committee and Notre Dame Graduate Studies Research and Advisory Council. Marc holds a BS from Miami University (Ohio).

Ramon Iglesias, MD
Co-Founder, Chief Innovation Officer

Dr. Iglesias is a nationally recognized urogynecologist with more than 30 years in private practice in Miami, FL. His increasing commitment to help improve the quality of life for individuals with pelvic floor disorders, coupled with his deep understanding of pelvic anatomy, and his passion for innovation and design drove him to develop novel products to address this highly-underserved market. And in 2016 together with Marc Beer and Yolanda Lorié, he founded Renovia.

Ramon is a lifetime Fellow of American College of Obstetrics and Gynecology (ACOG), as well as Board Certified in OBGYN. He graduated from the University of Miami’s School of Medicine and went on to complete his residency at Washington University School of Medicine in St. Louis, MO.

Ramon was active in many community projects including, Founder/Director of OBGYN at Rafael Peñalver Medical Clinic and Community Center, Director of OBGYN at both St. John Bosco’s Medical Clinic and Camilus House Health Concern.

Ramon was involved in several successful start-ups including Planet Symphony, GEO-Cities and POD’s Louisiana. And, on his mission to improve women’s healthcare, Dr. Iglesias founded UBS and Remendium Labs and has 2 issued patents and over 25 patents pending. Remendium Labs was established for the sole purpose of preventing and treating pelvic floor dysfunction. Leva, his first invention, is a medical device that incorporates time tested methods with innovative technology to bring to an underserved population a new and effective non-invasive treatment for incontinence.

Yolanda Lorié
Co-Founder, EVP, Finance & BD

Yolanda has over 25 years of experience in business administration for various private ventures, including Vice President of one of the largest publishers of bilingual inflight magazine and hotel books in Central and South America and CEO of a publishing company that produced bilingual medical newsletters, brochures and publications for hospitals including HealthSouth, Tenet and Columbia Hospitals. Yolanda, together with Marc Beer and Dr. Ramon Inglesias founded Renovia in 2016.

Yolanda was also active in community service as Manager/liaison for Medicaid at the St. John Bosco Medical Clinic, Advisory Committee Member for the City of Miami International Hispanic Conference, and Committee Member for Do the Right Thing of Miami.

A serial entrepreneur, Yolanda has been involved in several start-ups including Planet Symphony, Geo- Cities and POD’s Louisiana. Yolanda was a founder in Remendium Labs a company dedicated to the treatment and prevention of pelvic floor disorders, as well as Renovia Inc.

William Dull
Chief Commercial Officer

William serves as Renovia’s Chief Commercial Officer overseeing global commercial and company operations. William brings more than 30 years of senior leadership experience as a life science executive. As an accomplished entrepreneur, he has built, developed and led high-performing integrated teams and partnerships from early-stage research and development to successful domestic and international commercialization. He has built businesses and advanced value propositions to deliver significant revenue growth for start-up and mid-sized biopharmaceutical companies and biologic manufacturing organizations.

William joined Renovia from Aegerion Pharmaceuticals where he developed innovative solutions that solved complex patient problems. At Aegerion he led global marketing, commercial operations, consumer engagement and training in the launch of two therapeutic brands. Prior to joining Aegerion, William held global executive positions of increasing responsibilities in strategic planning, sales and marketing, patient advocacy and new product commercialization for therapeutics, manufacturing operations and genetic testing. William holds a Bachelor of Science degree in Business Administration from Georgia State University.

Jennifer Labus
Chief Marketing Officer

A global brand builder, Jennifer offers a passion for driving business results that has led to her success in developing and executing integrated marketing efforts behind blue chip brands within healthcare, consumer goods, and sustainability programs. ​

Having both agency and client-side experience, Jennifer has worked on some of the world’s largest brands and for some of the world’s top healthcare companies, including Pfizer, Johnson & Johnson, AstraZeneca, Shire, Regeneron, Novartis, Vertex, GSK, Lundbeck, Merck, Janssen, Sanofi-Aventis, MundiPharma, MSD, Resolute Oncology, Pfizer Consumer Healthcare, Pfizer Animal Health, and Zoetis. Her category experience includes women’s health, cardiovascular, fertility, respiratory, diabetes, CNS, endocrinology, oncology, pain, vaccines, ophthalmology, HIV, erectile dysfunction, animal health, and over-the- counter products. ​

In 2001, Jennifer migrated over to the client side as a marketing director for Pfizer, overseeing strategy, integrated marketing initiatives and innovative platforms for Celebrex, Bextra, and was a key lead in driving the successful launch of Chantix. She then shifted back to the agency side where she helped establish Nitro, later SapientNitro, as an important new digital marketing agency network. More recently, Jennifer helped Pfizer as a long-term marketing consultant, overseeing strategy and integrated marketing initiatives for Pristiq, Levoxyl, Dilantin, and Caverject.​

Jennifer’s career has taken her around the world with agency management roles in Europe and China. And now with her extensive healthcare marketing experience, Jennifer brings her enthusiasm, energy and insights to lead the Renovia marketing team and help change the standard of care for individuals with pelvic floor disorders.

José Bohorquez, PhD
Chief Scientific Officer

José Bohorquez, PhD has more than 15 years of experience leading technology and product development. His areas of expertise include biosensors and medical devices, integrated circuits, and the Internet of Things (IoT). Previously, Dr. Bohorquez was co-founder and CEO of Myolex (a.k.a. Skulpt), where he led the development and commercialization of one medical device and two award-winning consumer devices. He was also previously a Principal Consultant at T-Var Semiconductor and a Senior Engineer at Bitwave Semiconductor. He has co-authored fifteen peer-reviewed publications, four issued patents, and ten pending patents. Dr. Bohorquez has a Bachelor’s and Master’s degree in electrical engineering from the University of Florida (suma cum laude). He also holds a PhD in electrical engineering and computer science from MIT with a minor in business administration from the Sloan School of Management. He has received several honors and awards including the MIT Presidential Fellowship, the University of Florida Gator100 Award, two CES Innovation Awards, and the Best of What’s New Award from Popular Science. Dr. Bohorquez is a US citizen and is fluent in English and Spanish.

Jennifer Cermak, PhD
Clinical Development Advisor

Dr. Jennifer Cermak has 19 years R&D experience focused on the formation, early discovery and clinical development strategy of biotechnology companies from candidate selection through Phase IV global clinical trials for drugs, biologics and devices. She has served on the Executive Management Team of several biotechnology startup companies, participating in Series A through IPOs and post-merger integrations. She was a member of GSK’s CEO’s Future Strategy group. She led Flex Pharma to the discovery and clinical development of its lead compound to treats cramps and spasticity. She holds a Ph.D. in Pathology from Boston University School of Medicine and completed her postdoctoral fellowship in the Department of Surgery at Harvard Medical School.